

Curriculum Vitae

Dott.ssa CHIARA GABBI

Data di Nascita: 3 Ottobre 1977

Luogo di Nascita: Correggio, (Reggio Emilia)

Telefono personale: 328.8319462

E-mails: cgabbi@alumni.harvard.edu; chiara917@gmail.com

POSIZIONI ATTUALI

- 2018-attuale **Medico Specialista – Responsabile ambulatorio lipidologia e medicina metabolica**
Humanitas Medical Care, Milano
- 2015-attuale **Consulente Medico e Scientifico**
Libera Professione, Reggio Emilia, Italia
- 2020-attuale **Ricercatrice affiliata (Anknuten)**
Karolinska Institutet, Stoccolma, Svezia

FORMAZIONE

- 2017-2018 **Certificazione in “Global Clinical Scholar Research Training – Drug development and clinical trials concentration”**
Harvard Medical School, Boston, Massachusetts, USA
Voto: “commendation”
- 2008-2011 **PhD – Dottore di Ricerca in Scienze Mediche**
Karolinska Institutet, Stoccolma, Svezia
- 2007-2008 **Master (Licentiate) in Scienze Mediche**
Karolinska Institutet, Stoccolma, Svezia
- 2002-2007 **Specializzazione in Medicina Interna e Medicina d’Urgenza**
Università degli Studi di Modena e Reggio Emilia
Voto: 110/110 con lode
- 1996-2002 **Laurea in Medicina e Chirurgia**
Università degli Studi di Modena e Reggio Emilia
Voto: 110/110 con lode

ALTRI TITOLI

- 2020 **“Oxford Women Leadership Development Program”** – corso leadership (6 settimane)
Oxford University, Saïd Business School, UK

ABILITAZIONI

- 2020 **Abilitazione Scientifica Nazionale a Professore Associato (06/D2 – endocrinologia, nefrologia e scienze dell’alimentazione e del benessere)**
Ministero Istruzione Università e Ricerca
- 2018 **Abilitazione Scientifica Nazionale a Professore Associato (05/F1 – biologia applicata)**
Ministero Istruzione Università e Ricerca
- 2003 **Abilitazione alla Professione di Medico Chirurgo**
Ministero Istruzione Università e Ricerca

PREGRESSE ESPERIENZE PROFESSIONALI

- 2011-2014 **Research Assistant Professor**
Università di Houston, Houston, Texas, USA

- 2009-2011 **Research Associate 1**
Università di Houston, Houston, Texas, USA
- 2007-2011 **Dottoranda**
Karolinska Institutet, Stoccolma, Svezia
- 2006-2007 **Assegnista di Ricerca**
Karolinska Institutet, Stoccolma, Svezia
- 2002-2006 **Medico Specializzanda in Medicina Interna**
Policlinico di Modena, Modena

INCARICHI ISTITUZIONALI

- 2013 **Ministero della Salute**
Presidente della Commissione finale di valutazione dei progetti di ricerca finalizzata GR2011-2012. Roma, 19-20 Dicembre, 2013
- 2012 **Ministero della Salute**
*Membro della Commissione finale di valutazione dei progetti di ricerca finalizzata GR2010-2011
Roma, 3-5 Maggio, 2012*

ALTRI INCARICHI

- 2019 **Consulente** (consulenza, coordinamento e gestione tecnica delle attività del progetto “Emilia Romagna International 2018-2019”)
ART-ER – Società consortile della regione Emilia Romagna, Bologna
- 2019 **Consulente** (ottimizzazione e sviluppo delle attività di coordinamento e gestione dei servizi dedicati al sostegno della ricerca istituzionale dell’Istituto Nazionale dei Tumori)
IRCCS Istituto Nazionale dei Tumori, Milano
- 2017-attuale **Cultore della Materia – Medicina Interna**
Università di Modena e Reggio Emilia
- 2011-2017 **Ricercatrice affiliata (Anknuten)**
Karolinska Institutet, Stoccolma, Svezia

REVISORE PER ENTI FINANZIATORI LA RICERCA BIOMEDICA

- Dal 2020 **Bulgarian National Science Fund**
Expert Reviewer
- Dal 2017 **Commissione Europea**
Expert Reviewer per MSCA-IF
- 2014 **NIH**
Early Career Reviewer, Center for Scientific Review, National Institutes of Health, Bethesda, Maryland, USA
- 2011-2015 **Ministero della Salute**
Revisore Ad-hoc

INCARICHI DI DOCENZA

- 2020 **Docente al programma “GCSRT”**
Harvard Medical School, Boston, USA
- 2019 **Docente** al Master di II livello in Metodologia epidemiologica e biostatistica per la ricerca clinica.
Università di Milano-Bicocca, Milano
- 2015-oggi **Docente del corso per giovani ricercatori: “How to write a winning grant application”**

Corso tenutosi su incarico nelle seguenti Istituzioni: Università di Modena e Reggio Emilia; IRCCS-ASMN - Reggio Emilia; FAST – Milano; Azienda Ospedaliero-Universitaria di Parma; IRCCS San Raffaele Pisana, Roma; IRCCS Mario Negri – Milano; Azienda Ospedaliera Universitaria di Verona; IRCCS Istituto Nazionale dei Tumori – Milano; IRCCS Fondazione Ca' Granda Policlinico di Milano; IRCCS Bellaria – Bologna; Fondazione Angelo Bianchi Bonomi – Roma; Humanitas University – Milan; IRCCS Policlinico S. Matteo – Pavia; Fondazione The Bridge, Milano; Università di Macerata; IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma.

2017 **Docente del corso per giovani ricercatori: “Tutoring in Science: how to get the best out of yourself and others”**

Humanitas University, Milano

2017-oggi **Docente al corso per studenti di medicina “Unites States Medical License Examination”.**

Humanitas University, Milano.

2016-oggi **Docente del corso per giovani ricercatori: “Communicate Science: scientific writing and communication”**

Corso tenutosi su incarico nelle seguenti Istituzioni: Università di Modena e Reggio Emilia – Modena; IRCCS Istituto Nazionale dei Tumori – Milano; EyeCamp – Roma; Humanitas University, Milano.

2013-2014 **Componente del Collegio Docenti**

International PhD School in Clinical and Experimental Medicine

Università degli Studi di Modena e Reggio Emilia

2014 **Visiting Professor per il corso “Nuclear Receptors in Health and Disease”**

Università degli Studi di Modena e Reggio Emilia

PREMI RICEVUTI

2018 Premio internazionale “**Standout Women Award 2018**” – Montecitorio, Roma

2011 **EASL Young Investigator Award** - *European Association for the study of Liver, Berlino*

2007 **Giovanni Lorenzini Young Investigator Award** - *Giovanni Lorenzini Medical Foundation, New York*

2006 **EASL Young Investigator's Awards Bursary** - *European Association for the study of Liver, Vienna*

2006 **AISF Young Investigators Bursary** – *Associazione Italiana per lo Studio del Fegato, Roma*

FINANZIAMENTI OTTENUTI SU BASE COMPETITIVA COME RICERCATORE PRINCIPALE

2018 Ente Finanziatore: Swedish Cystic Fibrosis Association

Titolo del Progetto: *Lipid metabolism in cystic fibrosis*

2014 Ente Finanziatore: University of Houston – New Faculty Program

Titolo del Progetto: *Role of cholesterol in carcinogenesis of the gallbladder*

2011 Ente Finanziatore: *The Foundation BLANCEFLOR Boncompagni-Ludovisi, née Bildt, Svezia*

Titolo del Progetto: *Role of nuclear receptors in gallbladder adenocarcinoma*

2011 Ente Finanziatore: The Ruth and Richard Julin Foundation, Svezia

Titolo del Progetto: *Is nuclear receptors signaling defective in gallbladder adenocarcinoma?*

2010 Ente Finanziatore: Robert Lundbergs Memorial Foundation, Svezia

Titolo del Progetto: *Is nuclear hormone receptors signaling defective in gallbladder adenocarcinoma?*

PUBBLICAZIONI SCIENTIFICHE IN RIVISTE PEER-REVIEWED(ORCID ID: orcid.org/0000-0002-9764-4771)

1. Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD et al. **The GEN-COVID Investigators**. *Genetic mechanisms of critical illness in Covid-19*. Nature 2020. In press.
2. Benetti E, Giliberti A, Emiliozzi A, Valentino F et al. **GEN-COVID Multicenter Study**. *Clinical and molecular characterization of COVID-19 hospitalized patients*. PlosOne 2020. In press.
3. Benetti E, Tita R, Spiga O, Ciolfi A, Birolo G, Buruselles A, Doddato G, Giliberti A, Marconi C, Musaccia F, Pippucci T, Torella A, Trezza A, Valentino F et al. **GEN-COVID Multicenter Study**. *ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population*. Eur J Hum Genet. 2020 Jul 17. In press (IF: 4.349 - PMID: 7366459)
4. **Gabbi C**, Bertolotti M. *Reduced Multidrug Resistance-Associated Protein 2 in ticlopidine-induced cholestatic liver injury*. Dig Liver Dis, 2020 Feb;52(2):236-238. (IF: 3.037 - PMID: 31732442)
5. **Gabbi C**, Bertolotti M. *Drug-Induced Liver Injury — Types and Phenotypes*. N Engl J Med. 2019 Oct 3;381(14):1395-1396. (IF: 70.670 - PMID: 31577894)
6. Song X, Wu W, **Gabbi C**, Dai YB, So M, Chaurasiya SP, Wang L, Warner M, Gustafsson JÅ. *Retinal and optic nerve degeneration in liver X receptor β knockout mice*. PNAS, 2019 Aug 13;116(33):16507-16512. (IF: 9.504 - PMID: 31371497)
7. Agarwal N, Iyer D, **Gabbi C**, Saha P, Patel SG, Mo Q, Chang B, Goswami B, Schubert US, Kopp JB, Lewis DE, Balasubramanyam A. *HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXR- α and PPAR- α dysregulation: implications for HIV-specific pathogenesis of NAFLD*. Scientific Reports, 2017 Oct 17;7(1):13362 (IF: 4.122 - PMID: 29042644)
8. **Gabbi C**, Bertolotti M. *LXRs and copper metabolism: new frontiers for the oxysterol receptors*. Hepatology 2016 Oct 64(4):1371. (IF: 14.079 - PMID: 26946056 - letter)
9. Carulli L, **Gabbi C**, Bertolotti M. *Bile acids and non-alcoholic fatty liver disease: an intriguing relationship*. Hepatology 2016;63:1739-40. (IF: 14.079 - PMID: 26122405 - letter)
10. Candelaria NR, Addanki S, Zheng J, Nguyen-Vu T, Karaboga H, Dey P, **Gabbi C**, Vedin LL, et al. - *Antiproliferative Effects and Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells*. PlosOne, 2014;9(9):e106289 (IF: 2.766 - PMID: 25184494)
11. **Gabbi C**, Warner M, Gustafsson JÅ. *Action mechanisms of Liver X Receptors*. Biochem Biophys Res Commun, 2014;446(3):647-50 (IF: 2.559 - PMID: 24300092 - letter)
12. Carulli L, Del Puppo M, Anzivino C, Zambianchi L, **Gabbi C**, Baldelli E, Odoardi MR, Loria P, et al. *In vivo degradation of cholesterol to bile acids is reduced in patients receiving total parenteral nutrition*. Journal Parenteral Enteral Nutr, 2014; Feb;38(2):220-6 (IF: 4.249 - PMID: 23426743)
13. Archer A, Venteclev N, Mode A, Pedrelli M, **Gabbi C**, Parini P, Gustafsson JÅ. *Fasting-Induced FGF21 Is Repressed by LXR Activation via Recruitment of an HDAC3 Corepressor Complex in Mice*. Mol Endocrinol, 2012;26(12):1980-90. (IF: 3.993 - PMID: 23073827)
14. Xia X, Jung D, Webb P, Zhang A, Zhang B, Li L, Ayers S, **Gabbi C**, et al. *Liver X Receptor β and Peroxisome Proliferator-Activated Receptor δ regulate cholesterol transport in cholangiocytes*. Hepatology, 2012;56(6):2288-96. (IF: 14.079 - PMID: 22729460)
15. **Gabbi C**, Bertolotti M, Anzivino C, Macchioni D, Del Puppo M, Ricchi M, Carubbi F, Tagliafico E, et al. *Effects of bile duct ligation and cholic acid administration in two rat models of Non-alcoholic fatty liver disease*. Digestive and Liver Disease, 2012;44(12):1018-26 (IF: 3.287 - PMID: 22883218)
16. **Gabbi C**, Gustafsson JÅ. *Bile Acids in Non-Alcoholic Steato-Hepatitis: inserting nuclear receptors into the circle*. Hepatology, 2012;56(5):2008-9 (IF: 14.079 - PMID: 22535668 - letter)
17. **Gabbi C**, Kong X, Suzuki H, Kim, HJ, Gao M, Jia X, Ohnishi H, Ueta Y, et al. *Central diabetes insipidus associated with impaired renal aquaporin-1 expression in mice lacking the Liver X Receptor β* . PNAS, 2012; Feb 21;109(8):3030-4 (IF: 9.504 - PMID: 22323586)

18. Korach-André M, Archer A, **Gabbi C**, Barros RP, Pedrelli M, Steffensen KR, Pettersson AT, Laurencikienė J, et al. *Liver X Receptors regulate de novo lipogenesis in a tissue specific manner in C57BL/6 female mice*. Am J Physiol Endocrinol Metab, 2011 Jul;301(1):E210-220 (IF: 4.018 - PMID: 21521718)
19. Bertolotti M, Del Puppo M, Corna F, Anzivino C, **Gabbi C**, Baldelli E, Carulli L, Loria P, et al. *Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism*. Nutr Met Cardio Dis, 2011 May 3 (IF: 3.318 - PMID: 21546230)
20. **Gabbi C**, Kim HJ, Barros R, Korach-André, Warner M, Gustafsson JÅ. *Estrogen-dependent gallbladder carcinogenesis in LXR β female mice*. PNAS 2010 Aug 17;107(33):14763-8 (IF: 9.504 - PMID: 20679224)
21. Fan X, **Gabbi C**, Chen G, Andersson L, Kim HJ, Warner M, Gustafsson JÅ. *Gonadotropin-positive pituitary tumors accompanied by ovarian tumors in aging female ER β mice*. PNAS, 2010; Apr 6;107(14):6453-8 (IF: 9.504 - PMID: 20308571)
22. Barros R, **Gabbi C**, Morani A, Warner M, Gustafsson JÅ. *Participation of ER α and ER β in glucose homeostasis in skeletal muscle and white adipose tissue*. Am J Physiol Endocrinol Metab. 2009;297:E124-33 (IF: 4.018 - PMID: 19366879)
23. **Gabbi C**, Warner M, Gustafsson JÅ. *Liver X Receptor β : Emerging Roles in Physiology and Diseases*. Mol Endocrinol, 2009 Feb;23(2):129-36 (IF: 3.993 - PMID: 19074550)
24. **Gabbi C**, Kim HJ, Hultenby K, Bouton D, Toresson G, Warner M, Gustafsson JÅ. *Pancreatic exocrine insufficiency in LXR β -/- mice is associated with a reduction in aquaporin-1 expression*. PNAS, 2008; Sep 30;105(39):15052-7 (IF: 9.504 - PMID: 18806227)
25. Bertolotti M, **Gabbi C**, Anzivino C, Carulli L, Loria P, Carulli N. *Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: insight from evidence on hepatic cholesterol degradation and gallstone disease in humans*. Current Medicinal Chemistry, 2008;15(22):2271-84 (IF: 3.09 - PMID: 18781949)
26. Bertolotti M, Del Puppo M, **Gabbi C**, Corna F, Carulli L, Pellegrini E, Zambianchi L, Anzivino C, et al. *Correlation between plasma levels of 7 α -hydroxy-4-cholesten-3-one and cholesterol 7 α -hydroxylation rates in vivo in hyperlipidemic patients*. Steroids 2008;73:1197-202 (IF: 2.523 - PMID: 18582481)
27. Kim HJ, Fan X, **Gabbi C**, Yakimchuk K, Parini P, Warner M, Gustafsson JA. *Liver X receptor β (LXR β): a link between β -sitosterol and amyotrophic lateral sclerosis-Parkinson's dementia*. PNAS 2008;105:2094-9 (IF: 9.504 - PMID: 18238900)
28. **Gabbi C**, Carubbi F, Losi L, Loria P, Costanzini M, Bertolotti M, Carulli N. *Non-alcoholic fatty liver disease induced by leuprorelin acetate*. Jou Clin Gastro 2008;42(1):107-110 (IF: 2.968 - PMID: 18097299)
29. Bertolotti M, **Gabbi C**, Anzivino C, Carulli L, Carulli N. *Replay to: Increased synthesis of bile acids in gallstone disease is a global finding and not a peculiar condition solely in Chile*. Hepatology 2008;47:1797-1798 (IF: 14.079 - PMID: n.a. - letter)
30. Bertolotti M, **Gabbi C**, Anzivino C, Carulli L, Carulli N. *Changes in Bile Acid Synthesis in Gallstone Diseases: Cause, Consequence, or Neither?* Hepatology 2007;46:1664 (IF: 14.079 - PMID: 17969051 - letter)
31. Bertolotti M, **Gabbi C**, Anzivino C, Crestani M, Mitro N, Del Puppo C, Godio C, De Fabiani E, et al. *Age-related changes in bile acid synthesis and hepatic nuclear receptor expression*. Eur J Clin Inv 2007;37:501-508 (IF: 3.086 - PMID: 17537158)
32. Bertolotti M*, **Gabbi C***, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, et al. *Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis*. Eur J Clin Inv 2006;36:170-175. *These authors contributed equally to the paper (IF: 3.086 - PMID: 16506961)

33. **Gabbi C**, Bertolotti M, Iori R, Rivasi F, Stanzani C, Maurantonio M, Carulli N. *Acute abdomen associated with Schistosomiasis of the appendix*. Dig Dis Sci 2006;51:215-217 (IF: 2.22 - PMID: 16416239)
34. Bertolotti M, Maurantonio M, **Gabbi C**, Anzivino C, Carulli N. *Review article: hyperlipidaemia and cardiovascular risk*. Aliment Pharmacol Ther 2005;22(Suppl. 2):28-30 (IF: 7.357 - PMID: 16225468)
35. Maurantonio M, Venezia L, Carulli L, Lombardini S, **Gabbi C**, De Santis M, Luppi G, Rigo G, et al. *Cholestatic icterus: is there still a role for the clinic?* Ann Ital Med Int 2004;19:131-143 (IF: n.a. - PMID: 15317275)

SPECIAL ARTICLES

36. Sauer RM, **Gabbi C**. *Grantsmanship writing tips: significance, innovation and impact*. Eur J Intern Med. 2019 Jul;65:26-28. (IF: 3.282 - PMID: 30803834)
37. **Gabbi C**, Sauer RM. *Grantsmanship writing tips: the experimental design*. Eur J Intern Med. 2019 Jun;64:21-23. (IF: 3.282 - PMID: 30819603)
38. **Gabbi C**, Sauer RM. *Grantsmanship writing tips: background, hypothesis and aims*. Eur J Intern Med. 2019 Mar;61:25-28. (IF: 3.282 - PMID: 30777596)
39. Sauer RM, **Gabbi C**. *Grantsmanship: What? Who? How?*. Eur J Intern Med. 2018 Nov;57:22-24. (IF: 3.282 - PMID: 30396589)

PUBBLICAZIONI SELEZIONATE DI ABSTRACTS SCIENTIFICI IN RIVISTE PEER-REVIEWED

1. **Gabbi C**, Anzivino C, Baldelli E, Carulli L, Bertolotti M. *Circulating fibroblast growth factor 21 regulates bile acids homeostasis in cholestatic patients*. J Hepatol 2019; 70:e141-e382.
2. **Gabbi C**, Kim HJ, Sweed N, Warner M, Gustafsson JÅ. *Liver X Receptor β controls Aquaporin-1 and Aquaporin-4 expression and a sex-specific, caveolin-dependent cellular localization of Aquaporin-4 in the hepatocytes*. Hepatology 2013; 58:107A. (IF: 14.079)
3. **Gabbi C**, Kim HJ, Sweed N, Warner M, Gustafsson JÅ. *Liver X Receptor β controls hepatic expression of aquaporin-1 and aquaporin-4 and a gender-specific, caveolin-dependent cellular localization of aquaporin-4*. J Hepatol 2013; 58:S385. (IF: 14.911)
4. Candelaria NR, Addanki S, Zheng J, Nguyen-Vu T, Karaboga H, Dey P, **Gabbi C**, Vedin LL, et al. - *Antiproliferative Effects and Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells*. Cancer Research 2013; 73 (8) Suppl.1. (IF: 9.130)
5. **Gabbi C**, Kim HJ, Hultenby K, Warner M, Gustafsson JÅ. *LXR β regulates the expression of aquaporin-1 and aquaporin-8 in gallbladder cholangiocytes*. Hepatology 2011; 54:767A-768A. (IF: 14.079)
6. Li LF, Zhang AJ, Zhang B, **Gabbi C**, Sieglaff DH, Chen G, Huang P, Baxter J, et al. *Liver X Receptors inhibit proliferation through KLF4 in human cholangiocarcinoma*. Hepatology 2011; 54: 765A-&66A. (IF: 14.079)
7. **Gabbi C**, Warner M, Gustafsson JÅ. *LXR β , the physiological regulator of the expression of aquaporin-1 and aquaporin-8 in gallbladder cholangiocytes*. J Hepatol 2011; 54(Suppl. 1):S23. (IF: 14.911)
8. Bertolotti M, **Gabbi C**, Anzivino C, Baldelli E, Carulli L, Carulli N. *Nuclear receptors and obstructive cholestasis in Humans: increased hepatic expression of short heterodimer partner: a protective response?*. Internal and emergency medicine 2008; 3:82. (IF: 2.453)
9. Bertolotti M, **Gabbi C**, Anzivino C, Tagliafico E, Carulli L, Rossi A, Loria P., Carulli N. *Hepatic expression of nuclear receptors and biliary transporters in human cholesterol gallstone disease*. J Hepatol 2007; 46(Suppl. 1):S119. (IF: 14.911)
10. Bertolotti M, Gabbi C, Anzivino C, Macchini D, Crestani M, Mitro N, Del Puppo M, Rossi A, et al. *Role of hepatic expression of nuclear receptors on bile acids synthesis and modulation with age*. Internal and emergency medicine 2006; 1:16S. (IF: 2.453)

11. **Gabbi C**, Bertolotti M, Anzivino C, Macchioni D, Crestani M, Mitro N, Del Puppo M, Carulli L, et al. *Influence of age on bile acid synthesis: role of hepatic expression of nuclear receptors.* Atherosclerosis 2006;7(3). (IF: 4.467)
12. Anzivino C, Bertolotti M, **Gabbi C**, Ricchi M, Tagliafico E, Tenedini E, Carulli L, Carubbi F, et al. *Molecular regulation of sterol metabolism by bile acids in cultured human hepatocytes.* Atherosclerosis 2006;7(3). (IF: 4.467)
13. Bertolotti M, **Gabbi C**, Anzivino C, Crestani M, Mitro N, Del Puppo M, Rossi A, Carulli L, et al. *Hepatic nuclear receptors in human cholelithiasis: a link with insuline resistance?* Atherosclerosis 2006;7(3). (IF: 4.467)
14. Bertolotti M, **Gabbi C**, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Carulli L, et al. *Hepatic expression of PPAR-gamma coactivator 1 (PCG-1) is reduced in human cholelithiasis.* J Hepatol 2006; 44(Suppl. 2):S120. (IF: 14.911)
15. **Gabbi C**, Bertolotti M, Anzivino C, Macchioni D, Crestani M, Mitro N, Del Puppo M, Carulli L, et al. *Influence of age on bile acid synthesis: role of hepatic expression of nuclear receptors.* Dig Liv Dis 2006;38(3):A73-A74. (IF: 3.287)
16. **Gabbi C**, Bertolotti M, Anzivino C, Ricchi M, Tagliafico E, Tenedini E, Carulli L, Carubbi F, et al. *Molecular regulation of cholesterol metabolism in cultured human hepatocytes.* Nutr Metab Cardiovas Dis 2005;1(Suppl.1):S13. (IF: 3.318)
17. Bertolotti M, Anzivino C, **Gabbi C**, Tenedini E, Tagliafico E, Ricchi M, Carulli L, Loria P, et al. *Role of nuclear receptors in the molecular regulation of cholesterol homeostasis in cultured human hepatocytes.* Atherosclerosis 2005;6:96-97. (IF: 4.467)
18. Bertolotti M, **Gabbi C**, Anzivino C, Crestani M, Mitro N, Del Puppo M, Carulli L, Rossi A, et al. *Hepatic nuclear receptor expression and regulation of bile acid synthesis in humans.* Hepatology 2004;40(4)Suppl. 1:495A. (IF: 14.079)
19. Bertolotti M, **Gabbi C**, Anzivino C, Crestani M, Mitro N, Godio C, De Fabiani E, Del Puppo M, et al. *Nuclear receptors and regulation of bile acid synthesis in humans.* Nutr Metab Cardiovas Dis 2004;14(5):297. (IF: 3.318)

LIBRI PUBBLICATI

1. Autore: Chiara Gabbi
Titolo: "Studies on the oxysterol receptor LXR β : linking cholesterol metabolism to water transport and cell proliferation." Editore: Karolinska Institutet. Anno: 2011. ISBN: 978-91-7457-225-4
2. Autore: Chiara Gabbi
Titolo: "Studies on the phenotype of LXR β -/- mice: from malabsorption syndrome to amyotrophic lateral sclerosis". Editore: Karolinska Institutet. Anno: 2008. ISBN: 978-91-7409-198-4

SELEZIONATE PRESENTAZIONI A CONGRESSI E CONFERENZE

1. EuroCholangioNet COST Action Meeting. **Presentazione Orale**. "Liver X Receptor β signaling in the development of gallbladder cholangiocarcinoma. Novel sex-related diagnostic and prognostic markers." *University of Malta – 12-13 Settembre, 2019*
2. XXV International Bile Acid Meeting – Falk Symposium 211. **Presentazione Poster**: "Circulating Fibroblast Growth Factor 21 is increased during cholestasis and correlates with hepatic expression of genes involved in regulating bile acids homeostasis". *Dublin, Ireland – July 6-7, 2018*
3. Evento Annuale della Fondazione ISSNAF (Italian Scientists and Scholars of North America Foundation). **Seminario**: "Career Symposium for Young Investigators: funding opportunities for reintegration in Italy". *Washington DC, USA – 18 Ottobre 2016*
4. Gained in Translation – **Seminario**: "Liver X Receptor B: the paradigm of cholesterol and sex hormones in carcinogenesis". *IRCCS Reggio Emilia, 21 Maggio 2015*

5. 64th Annual Meeting of the American Association for the Study of Liver Diseases. **Presentazione Poster:** "Liver X Receptor β controls Aquaporin-1 and Aquaporin-4 expression and a sex-specific, caveolin-dependent cellular localization of Aquaporin-4 in the hepatocytes". *Washington DC – 1-5 Novembre 2013*
6. Annual Meeting of Italian Scientists and Scholars of North America Foundation. **Moderatore:** "Career Symposium for young investigators". *Washington DC – 28-29 Ottobre 2013*
7. 54th International Conference on Biosciences of Lipids. **Comunicazione Orale:** "The oxysterol receptor LXR β is a regulator of body water balance". *Bari – 17-21 Settembre 2013, 2013*
8. University of Milano-Bicocca. **Seminario:** "Liver X Receptor β , beyond cholesterol metabolism, at the frontiers of water transport and cell proliferation". *Monza – 12 Dicembre, 2012*
9. Yale Liver Center. **Seminario:** "Liver X Receptor beta, beyond cholesterol metabolism, in the frontiers of water transport and cell proliferation". *Yale, New Haven, CT – 4 Giugno, 2012*
10. International Doctorate School in Clinical and Experimental Medicine of the University of Modena and Reggio Emilia. **Comunicazione Orale:** "Liver X Receptor beta, beyond cholesterol metabolism, in the frontiers of neurodegeneration, malabsorption and cancer". *Modena, 20 Settembre, 2011*
11. 46st Annual Meeting of the European Association for the Study of Liver (EASL). **Comunicazione Orale:** "LXR β , the physiological regulator of the expression of aquaporin-1 and aquaporin-8 in gallbladder cholangiocytes". *Berlino 29 Marzo-1 Aprile 2011*
12. 6th Conference of Italian Researchers in The World. **Comunicazione Orale:** "Sex Differences in Nuclear Receptor Action". *Houston, Texas – 4 Dicembre, 2010*
13. Baylor Endocrinology Grand Rounds – Baylor College of Medicine. **Seminario:** "Studies on the oxysterols receptor LXR β linking cholesterol metabolism to water transport and cell proliferation". *Houston, Texas – 21 Ottobre, 2010*
14. Euro Science Open Forum. **Comunicazione Orale:** "Sex Differences in Nuclear Receptor Action". *Torino - 2-7 Luglio, 2010*
15. Summer School on Endocrinology. **Seminario:** "Genetics of Dyslipidemia and Cholesterol Metabolism Disorders". *Bregenz – 27-31 Luglio, 2008*
16. 7th World Congress on Trauma, Shock, Inflammation and Sepsis. **Seminario:** "LXR: Integrated Metabolism and Atherosclerosis". *Monaco – 13-17 Marzo, 2007*
17. XIX International Bile Acid Meeting – Falk Symposium 155. **Presentazione Poster:** "Bile duct ligation ameliorates hepatic steatosis and hypertriglyceridemia in rats by inhibiting lipogenic genes expression independently of FXR/SHP activation". *Friburgo – 6-7 Ottobre, 2006*
18. XIV International Symposium on Atherosclerosis. **Comunicazione Orale:** "Influence of age on bile acids synthesis: role of hepatic expression of nuclear receptors". *Roma – 18-22 Giugno, 2006*
19. 41st Annual Meeting of the European Association for the Study of Liver (EASL). **Presentazione Poster:** "Hepatic expression of PPAR-gamma coactivator 1 (PCG-1) is reduced in human cholelithiasis." *Vienna- 26-30 Aprile, 2006*
20. XXXIX Annual General Meeting of the Italian Association for the Study of Liver (AISF). **Presentazione Poster:** "Influence of age on bile acid synthesis: role of hepatic expression of nuclear receptors". *Rome, 16-17 Febbraio, 2006*
21. 5th Conferenza sul Rischio Cardiovascolare. **Comunicazione Orale:** "Aging and bile acids synthesis: role of nuclear receptors". *Ferrara – 4 Novembre, 2005*
22. XXXVIII Riunione Generale Annuale della Società Italiana per lo Studio del Fegato. **Presentazione Poster:** "Nuclear receptor expression in human liver and regulation of bile acid synthesis". *Roma – 17-18 Febbraio, 2005*
23. 4th Conferenza sul Rischio Cardiovascolare. **Comunicazione Orale:** "Nuclear Receptors expression in human liver during aging". *Modena – 4 Novembre, 2005*
24. 106th Congresso della Società Italiana di Medicina Interna. **Presentazione Poster:** "Acute abdomen associated with Schistosomiasis of the appendix". *Roma – 18-21 Ottobre, 2005*

25. 106th Congresso della Società Italiana di Medicina Interna. **Comunicazione Orale:** "Hydrophobic bile acids modulate the expression of genes involved in cholesterol and bile acid metabolism in cultured human hepatocytes". *Roma, 18-21 Ottobre, 2005*
26. Falk Symposium No 150 – disease Progression and Disease Prevention in Hepatology and Gastroenterology. **Presentazione Poster:** "Reduced hepatic expression of PCG-1 α in human cholelithiasis". *Berlino – 3,4 Ottobre 2005*
27. 105th Congresso della Società Italiana di Medicina Interna. **Comunicazione Orale:** "Hepatic expression of nuclear receptors and regulation of bile acid synthesis in humans". *Palermo - 23-26 Ottobre, 2004*
28. XV international Symposium on "DRUGS AFFECTING LIPID METABOLISM". **Comunicazione Orale:** "Regulation of bile acids synthesis in humans: role of hepatic expression of nuclear receptors". *Venezia– 24-27 Ottobre, 2004*
29. Falk Symposium No 141 – XVIII International Bile Acids Meeting. **Presentazione Poster:** "Influence of newly synthesized cholesterol on bile acids synthesis in humans". *Stoccolma, Svezia, 18-19 Giugno 2004*

REVISORE PER RIVISTE SCIENTIFICHE

Dal 2007	Clinical Endocrinology
Dal 2007	European Journal of Endocrinology
Dal 2012	FEBS Journal
Dal 2012	Journal of Clinical Investigation
Dal 2013	Cancer Epidemiology
Dal 2013	Journal of Liver: Disease & Transplantation
Dal 2015	PlosOne

APPARTENENZA A SOCIETA' SCIENTIFICHE

2012-Oggi	American Association for the Study of Liver Disease (AASLD)
2011-Oggi	European Association For the Study of Liver (EASL)
2010-Oggi	Italian Scientist and Scholars in North America Foundation (ISSNAF)
2015-2016	American Society of Cell Biology (ASCB)
2013-2014	American Association University Women (AAUW)
2003-2007	Società Italiana di Medicina Interna (SIMI)
2003-2008	Associazione Italiana per lo studio del fegato (AISF)

RUOLI DI LEADERSHIP RICOPERTI PRO-BONO

2011	Fondatrice di Young-ISSNAF (Italian Scientists and Scholars of North America Foundation), fondazione no profit nell'ambito della scienza e tecnologia
2015-2019	Membro del Consiglio di Amministrazione della Fondazione ISSNAF
2011-2016	Coordinatrice di Young-ISSNAF

LINGUE PARLATE

- Italiano – madrelingua
- Inglese – livello ottimo
- Svedese – livello elementare

22 marzo 2021

